MX2023004802A - Compuestos espiro heterocíclicos y métodos de uso. - Google Patents

Compuestos espiro heterocíclicos y métodos de uso.

Info

Publication number
MX2023004802A
MX2023004802A MX2023004802A MX2023004802A MX2023004802A MX 2023004802 A MX2023004802 A MX 2023004802A MX 2023004802 A MX2023004802 A MX 2023004802A MX 2023004802 A MX2023004802 A MX 2023004802A MX 2023004802 A MX2023004802 A MX 2023004802A
Authority
MX
Mexico
Prior art keywords
methods
spiro compounds
heterocyclic spiro
compounds
heterocyclic
Prior art date
Application number
MX2023004802A
Other languages
English (en)
Inventor
Brian Alan Lanman
Matthew R Kaller
Vu Van Ma
Dongcheng Dai
Alexander J Pickrell
Patricia Lopez
Nuria A Tamayo
Margaret Chu-Moyer
Abhisek Banerjee
Francesco Manoni
Jose M Medina
Kai Zhu
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2023004802A publication Critical patent/MX2023004802A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

La presente divulgación proporciona compuestos de Fórmula I que tienen actividad como inhibidores de la proteína mutante KRAS G12C. (ver fórmula). Esta divulgación también proporciona composiciones farmacéuticas que comprenden los compuestos, usos y métodos para tratar determinados trastornos, tales como el cáncer, que incluyen, pero sin limitación, cáncer de pulmón, cáncer de páncreas y cáncer colorrectal.
MX2023004802A 2020-10-27 2021-10-26 Compuestos espiro heterocíclicos y métodos de uso. MX2023004802A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2020123913 2020-10-27
PCT/US2021/056702 WO2022093856A1 (en) 2020-10-27 2021-10-26 Heterocyclic spiro compounds and methods of use

Publications (1)

Publication Number Publication Date
MX2023004802A true MX2023004802A (es) 2023-06-22

Family

ID=78650109

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023004802A MX2023004802A (es) 2020-10-27 2021-10-26 Compuestos espiro heterocíclicos y métodos de uso.

Country Status (7)

Country Link
US (1) US20230406860A1 (es)
EP (1) EP4237086A1 (es)
JP (1) JP2023549055A (es)
AU (1) AU2021370660A1 (es)
CA (1) CA3199082A1 (es)
MX (1) MX2023004802A (es)
WO (1) WO2022093856A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230107642A1 (en) 2020-12-18 2023-04-06 Erasca, Inc. Tricyclic pyridones and pyrimidones
WO2022266206A1 (en) 2021-06-16 2022-12-22 Erasca, Inc. Kras inhibitor conjugates
TW202337466A (zh) * 2022-01-06 2023-10-01 美商德洛斯股份有限公司 用於抑制ｒａｓ之組合物及方法
TW202334155A (zh) * 2022-01-06 2023-09-01 美商德洛斯股份有限公司 用於抑制ｒａｓ之組合物及方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20080540A1 (es) 2006-08-10 2008-06-08 Glaxo Group Ltd Compuestos 4-fenil-2-piridinil-metil sustituidos como moduladores de los canales de sodio con apertura por voltaje
AU2016245864C1 (en) * 2015-04-10 2021-09-09 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
CN116478132A (zh) 2016-07-12 2023-07-25 锐新医药公司 作为变构shp2抑制剂的2,5-双取代型及2,5,6-三取代型3-甲基吡嗪
MX2019008695A (es) 2017-01-23 2019-09-11 Revolution Medicines Inc Compuestos biciclicos como inhibidores alostericos de shp2.
MX2019008696A (es) 2017-01-23 2019-09-13 Revolution Medicines Inc Compuestos de piridina como inhibidores de shp2 alostericos.
JOP20190272A1 (ar) 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
ES2928576T3 (es) 2017-09-08 2022-11-21 Amgen Inc Inhibidores de KRAS G12C y métodos de uso de los mismos
EP3694848A1 (en) 2017-10-12 2020-08-19 Revolution Medicines, Inc. Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors
JP2021532157A (ja) * 2018-08-01 2021-11-25 アラクセス ファーマ エルエルシー がんを処置するための複素環式スピロ化合物およびその使用方法
CA3120383A1 (en) * 2018-11-29 2020-06-04 Araxes Pharma Llc Compounds and methods of use thereof for treatment of cancer
US20220056015A1 (en) 2018-12-20 2022-02-24 Amgen Inc. Kif18a inhibitors
CA3123044A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Heteroaryl amides useful as kif18a inhibitors
JP2022514268A (ja) 2018-12-20 2022-02-10 アムジエン・インコーポレーテツド Ｋｉｆ１８ａ阻害剤
CR20210387A (es) 2018-12-20 2021-08-19 Amgen Inc Inhibidores de kif18a
EP3908283A4 (en) * 2019-01-10 2022-10-12 Mirati Therapeutics, Inc. KRAS G12C INHIBITORS

Also Published As

Publication number Publication date
WO2022093856A1 (en) 2022-05-05
US20230406860A1 (en) 2023-12-21
JP2023549055A (ja) 2023-11-22
EP4237086A1 (en) 2023-09-06
CA3199082A1 (en) 2022-05-05
AU2021370660A1 (en) 2023-06-08

Similar Documents

Publication Publication Date Title
MX2023004802A (es) Compuestos espiro heterocíclicos y métodos de uso.
MX2023004518A (es) Compuestos espiro heterocíclicos y métodos de uso.
WO2020050890A3 (en) Kras g12c inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer
EA202092320A1 (ru) Гетеробициклические ингибиторы mat2a и способы использования для лечения злокачественной опухоли
MX2022012780A (es) Inhibidores de homologo de oncogen viral de sarcoma de rata kirsten (kras) triciclicos fusionados.
MX2021004624A (es) Derivados de 2-(2-acriloil-2,6-diazaspiro[3.4]octan-6-il)-6-(1h-in dazol-4-il)-benzonitrilo y compuestos relacionados como inhibidores de la proteina kras mutante g12c para inhibir metastasis de tumor.
JOP20210317A1 (ar) مثبطات غير متجانسة ثنائية الحلقة لـ mat2a وطرق استخدامها لعلاج السرطان
CR20210409A (es) Inhibidores aza-heterobicíclicos de mat2a y métodos de uso en el tratamiento de cáncer
ZA202104423B (en) Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
EA201400111A1 (ru) Ингибиторы mek и способы их применения
IL178675A0 (en) Monocyclic heterocycles as kinase inhibitors
AU2020281332A8 (en) Dna-dependent protein kinase inhibitor
ATE493418T1 (de) Dihydrofuropyrimidine als akt- proteinkinaseinhibitoren
MX2023006145A (es) Inhibidores de prmt5 novedosos.
UA85087C2 (en) Monocyclic heterocycles as kinase inhibitors
CR20220068A (es) Derivados de 2-morfolinopiridina sustituidos como inhibidores de la cinasa atr
JOP20220107A1 (ar) مثبطات egfr تفارغية وطرق استخدامها
WO2021011713A8 (en) Imidazopyrimidines as eed inhibitors and the use thereof
MX2021011524A (es) Inhibidores de proteina arginina n-metiltransferasa 5 (prmt5) y usos de los mismos.
MX2023003443A (es) Inhibidores de la proteína cinasa alfa 1 y métodos de uso.
AU2022367432A1 (en) Quinoline compounds as inhibitors of kras
MX2022008627A (es) Pirazolo-pirimidinas sustituidas y usos de las mismas.
MX2022015739A (es) Inhibidores alostericos de egfr y metodos de uso de estos.
ZA202201499B (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
MX2021011699A (es) Derivados de quinolina y su uso para el tratamiento del cancer.